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Autonomous proliferation and bcl-2 expression involving
haematopoietic cells in patients with myelodysplastic
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Summary In this work, we investigated the autonomous proliferation, bcl-2 expression and number of apoptotic cells in the bone marrow of
patients with confirmed diagnosis of myelodysplastic syndromes (MDS). Normal bone marrow cells obtained from donors of the Clinical
Hospital of this university were used as a control. The autonomous proliferation, evaluated by lonal culture without exogenous growth factor,
and the number of apoptotic cells in bone marrow kept for 10 days in liquid cultures at 3TC and 5% carbon dioxide, were significantly greater
in MDS patients than in control subjects (P = 0.001, Wilcoxon). However, bcl-2 expression, measured by immunocytochemistry, was
significantly lower in MDS patients than in normal individuals (P = 0.002, Wilcoxon). These results suggest that the high proliferation activity
in MDS patients may be counteracted by the high level of medullar cell death, which might be related to the lower bcl-2 expression.
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Myelodysplastic syndromes (MDS) consist of a group of acquired
haemopoietic disorders with evidence oftrilineage dysplasia and an
incidence of 30% of eventual transformation into acute myeloid
leukaemia (AML) (Ganser and Hoelzer. 1992: Loffler et al. 1992:
Willemze et al. 1993). An apparent paradox in MDS is that patients
with these disorders have peripheral cytopenias. despite frequently
having normo- or hypercellular bone marrow (Raza et al. 1995).
These contradictory findings may be explained by an excessive
intramedullary cell death in the face of normal or even enhanced
rates of proliferation. Recently. some studies have suggested that
the increased programmed cell death. or apoptosis. may cancel the
normal or high proliferation activity in MDS patients (Raza et al.
1995). One reason for this increased number of apoptotic cells
may be transcriptionally deregulated bcl-2 expression. bcl-2 was
initially detected at a translocation breakpoint in B-cell follicular
lymphomas and was subsequently shown to have a role in
preventing apoptosis (Korsmeyer. 1992: Vaux. 1993). The protein
is found in various fetal tissues destined for long-term survival and
in adult tissues in which apoptosis has an important homeostatic
role (Hockenbery et al. 1991). bcl-2 is expressed in the myeloid
lineage at the myeloblastic and promyelocytic stages ofdifferentia-
tion. diminishing with the maturation of cells into granulocytes
(Delia et al. 1992). Furthermore. the early cell death observed in
bone marrow cells of MDS patients suggests abnormalities in the
cell cycle control pathways. which can also affect cellular prolifer-
ation. For example. suppression of the apoptotic-enhancing effect
ofderegulated c-mvc by either bcl-2 or mutatedp53 allows expres-
sion of an unopposed proliferate signal (Vaux et al. 1988: Green et
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al. 1994). Moreover. the association between proliferation activity.
bc1-2 expression and apoptosis has not been previously determined.
In the present work. we examined bcl-2 expression. autonomous
colony formation (without exogenous growth factors) and
apoptosis in bone marrow cells from MDS patients with the aim of
identifying the process involved in the ineffective haemopoiesis
observed in this clonal disorder.
MATERIAL AND METHODS
Cases
bc1-2 expression was evaluated in all the patients (n = 15).
Autonomous colony formation (CFU-C) and apoptosis were studied
in 12 and 11 patients respectively. The MDS patients were defied
according to the FAB cooperative group (Bennett et al. 1982). Bone
marrow cells from 19 blood donors of the Clinical Hospital in this
universitv were used as control subjects (n = 11 forapoptosis. n = 15
for bcl-2 expression and n = 19 for autonomous proliferation). All
subjects gave informed consent and the study was approved by the
ethics committee of this hospital. A maximum of 3 ml of bone
marrow was allowed to be used for this study.
Bone marrow cell separation
Mononuclear cells were separated from 3 ml of heparinized bone
marrow by 30 mm centrifutation at 400g in Ficoll-Hypaque
(density 1.077g ml-l: PharmaciaFine Chemicals. Uppsala. Sweden).
The cells from the interface were washed three times with RPMI-
1640 (Sigma. St Louis. MO. USA) and counted for autonomous
colony formation culture. bc1-2 expression and apoptosis.
Assay for autonomous colony formation (CFU)
Assay with mononuclear cell suspensions was performed in 2 ml
ofagar cultures in 35-mm Petri dishes using 5 x l0W cells ml. The
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Figure 1 Autonorous colony proliferaton in Fe absence of exogenous
growth fators of bone marrow cels from MDS patients and control subjects
(P= 0.001, Wllcoxon)
Figure 3 Percentage of apoptotic cells from bone marrow of MDS patients
and control subjects, obtained after 10 days in liquid cultures (P= 0.001,
Wicoxon)
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Figwe 2 Percentage of mononuclear bcl-2+ cell expression from bone
marrow of MDS patents and control subjects (P = 0.002, Wicoxon)
medium used was Iscove's modified Dulbecco medium (Sigma)
containing 20% fetal calf serum (Sigma) and 0.6% agar. Colony
formation was studied without addition of any exogenous growth
factors. The plates were incubated at 370C in 5% carbon dioxide in
air at 100% humidity. Colonies were counted after 14 days at 35 x
magnification using a dissection microscope (Metcalf, 1984).
bc-2 expression (immunocytochemistry)
Cytocentrifuge preparations of mononuclear cells were fixed in
acetone at 40C and washed in Ths-buffered saline containing
Tween (TBSlTween 20, 50 mm Tns-HCI, 0.9% sodium chloride,
0.05% Tween 20, pH 7.6). Slides were incubated in a 1:40 dilution
of monoclonal mouse antibody to human bcl-2 oncoprotein in
phosphate-buffered saline (PBS) containing 2% bovine serum
albumin for 1 h, a 1:150 dilution of goat biotinylated anti-mouse
immunoglobulin in PBS for45 min and with alkaline phosphatase-
conjugated streptavidin (Dako) for 45 min. Between incubations,
slides were washed thoroughly with TBSiTween. Alkaline phos-
phatase activity was detected using a substrate of 0.2% naphthol
AS-MX phosphate. 2% dimethylformamide, 0.24% levamisole and
0.1% Fast Red TR salt in 0.01 M Ths-HCL, pH 8.1. Mononuclear
cells were counterstained using haematoxylin. All chemicals were
from Sigma (Maung et al, 1994). The percentage ofpositive bcl-2
mononuclear cells present in MDS patients and in control subjects
was calculated after counting at least 300 cells.
Apoptotc cells
Viability of mononuclear cells isolated from heparinized bone
marrow was determined by the trypan blue dye exclusion test.
The cells were resuspended in 20% serum/RPMI-1640 medium
(Gibco-USA) supplemented with 2 mm 1-' glutamnine, 100 U ml-'
penicillin and 100 gg mll streptomycin. The cells were seeded at
a density of 5 x 101 cells ml-l and incubated in an atmosphere of
95% air/5% carbon dioxide at 370C for 10 days. Cytocentrifuge
preparations from MDS bone marrow cells kept for 10 days in
culture were performed. The slides were then stained with haema-
toxylin and the apoptotic cells were determined under high power
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0 CancerResearch Campaign 1998(40x objective) in accordance with Koshida et al (1997) as
follows: overall shrinkage and homogeneously dark basophilic
nuclei: presence of nuclear fragments (apoptotic bodies); sharply
delineated cell borders surrounded by empty space: homogeneous
eosinophilic cytoplasm. The percentage of apoptotic cells was
calculated aftercounting at least 300 cells.
Statisticals analysis
Statistical comparison of the results from MDS patients and
control subjects was performed using the Wilcoxon test. A result
ofP < 0.05 was considered statistically significant.
RESULTS
The growth and differentiation of early bone marrow progenitor
cells (CFU/5 x 10' cells ml-') in the absence of any exogenous
growth factors, in patients with a confirmed diagnosis of
myelodysplastic syndrome (MDS) were significantly higher than
in control subjects (P = 0.001. Wilcoxon, Figure 1). Out of 12
patients. only two presented values similar to that of control
subjects. The percentage of positive mononuclear bc1-2 cells was
reduced in MDS patients in relation to normal individuals (P =
0.002. Wllcoxon, Figure 2). However, the percentage ofapoptotic
cells was significantly increased in MDS bone marrow cells in
relation to the percentage in control subjects (P =0.001, Wilcoxon,
Figure 3). We did not observe a correlation between bcl-2 expres-
sion. autonomous proliferation and FAB classification. It was not
possible to perform the correlation between bcl-2 expression
and apoptosis as almost all cells were in an advanced stage of
apoptosis by the tenth day ofculture (Figure 3).
DISCUSSION
Myelodysplastic syndromes (MDS) are clonal disorders of pluri-
potent haematopoietic stem cells, generally ofunknown aetiology.
occurring predominantly in the elderly, characterized by ineffective
haematopoiesis leading to blood cytopenias despite ofthe presence
of a hypercellular or normocellular bone marrow (Fenaux. 1996).
Recently. some studies have suggested that an important factor
involved in the peripheral cytopenias in MDS patients is an
increase in programmed cell death (apoptosis). In this regard, a
high range ofapoptosis was observed in this study when the MDS
cells were cultivated in liquid cultures and evaluated morphologi-
cally. These results corroborate the findings reported by Raza et al
(1995). who observed more than 75% ofapoptosis in stromal bone
marrow cells of the MDS patients using the in situ end-labelling
technique (ISEL). These findings are complementary as the ISEL
technique allows the study ofapoptosis atthe very early stages after
initial changes in DNA levels, whereas our morphological
approach reveals the late stages of apoptosis. Therefore. based on
these results and other reports (Clark and Lampert. 1990: Yoshida,
1993: Raza et al. 1995: Yoshida et al. 1995: Bogdanovic et al.
1997). we suggest that apoptosis is a mechanism responsible. at
least in part. for the ineffective haematopoiesis in MDS.
Alterations in the bc1-2 expression are involved in the regulation
of apoptosis (Gajewaki and Thompson. 1996: Kroemer. 1997). as
well as in the sensitivity of cells to a variety of cytotoxic drugs
(Kamesaki et al. 1993). In this regard. we observed a low bcl-2
expression in mononuclear MDS cells, suggesting that this proto-
oncogene may be involved in the high rate of cell death observed
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in this study. These findings suggest impairment in the pathways
involved in proliferation. differentiation and cell death. In this
field. we observed autonomous colony formation in the absence of
any exogenous haemopoietic growth factors in MDS patients.
These results support the hypothesis. in the literature. that early
cell death cancels high or normal proliferation activity (Raza et al.
1995). Autonomous proliferation activity seems to be related to
the autocrine production of some growth factors in acute myeloid
leukaemia (AML) (Young and Griffin. 1986: Bradbury et al. 1994:
Bradbury and Russell: 1995. Russel et al. 1995: Hu et al. 1996).
However. Shetty et al (1996). reported a relative absence or unde-
tectable levels of granulocyte-macrophage colony-stimulating
factor (GM-CSF) in MDS patients. which denotes another mecha-
nism involved in the progression of this disease. In this regard.
Soligo et al (1996). observed an overexpression ofGM-CSF and c-
kit receptors in MDS patients. suggesting an increased sensitivity
of bone marrow progenitors. leading to an autonomous colony
formation without exogenous growth factors. On the other hand.
patients with MDS have normal or elevated levels of erythropoi-
etin (Epo) (Jacobs et al. 1989) and activation of StatS by Epo is
impaired in these patients (Hoefsloot et al. 1997). Moreover. alter-
ations in genes that control the proliferation activity and cell death
can be involved in the autonomous colony formation observed in
our study. such as the c-mvconcogene (Nowak. 1992. Rajapaksa et
al. 1996) or a high p21 ras expression (Silva et al. 1997) Another
factor that could help to explain our results is the recent finding in
our laboratory (unpublished data) showing a high p53 expression
in MDS patients. Thep53 overexpression might be associated with
bcl-2 mRNA and protein reduction. probably because the 5'
untranslated region of the bcl-2 gene contains a p53-negative
responsive element, through which p53 may directly or indirectly
transcriptionally down-regulate the expression ofbcl-2 (Haldar et
al. 1994: Miyashita et al. 1994: Lepelley et al. 1995). Furthermore.
p53 stimulates the expression ofbar. a gene that encodes a domi-
nant inhibitor ofthe bcl-2 protein (Miyashita et al. 1994).
Although these results suggest a participation of bcl-2 expres-
sion in the high rate ofcell death in MDS patients. further investi-
gations are necessary to clarify the molecular mechanisms
involved in the progress of this disease. It has been demonstrated
that the cell-surface receptor FAS/APO-I (CD95) is able to trigger
apoptosis in a variety of cell types (Karawajew et al. 1997).
However. in relation to the FAS expression on MDS cells. Munker
et al (1996). described in 17 MDS patients that the average value
ofsoluble CD95 was not statistically different from normal control
subjects and no correlation was found with the FAB type.
In conclusion. the MDS cells with a higher baseline level of
growth stimulation may contribute to additional mutations and
progression of MDS to AML. Finally. autonomous proliferation
activity might be a good marker for myelodysplastic syndrome
diagnosis.
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